Researchers said they found that the vaccine was effective in preventing hospitalization and death in the age group, weighed against potential serious side effects.
The study did address cases of myocarditis that were seen after the second dose of the vaccine in older, mostly male teens and young men.
If the FDA advisory board approves the vaccine for use in the age group, a CDC advisory group would have to approve it and the CDC director would have to sign off on the guidance.
By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices.